Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacopo Giuliani

Showing results (21-30 of 134) with videos related to

Pageof 14
Sort By:
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 7, 2015
A path for diagnosis and therapy of colon cancer: a continuous quality improvementJacopo Giuliani, Marina Marzola
Clinical Lung Cancer|June 2, 2016
The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-InhibitorsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|January 4, 2018
[La combinazione di gemcitabina e oxaliplatino (GEMOX) nel trattamento del carcinoma pancreatico in fase avanzata di malattia: le notizie sulla mia morte sono state esagerate?]Jacopo Giuliani, Andrea Bonetti
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 21, 2013
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylateJacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease|May 28, 2018
Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costsJacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease|September 10, 2018
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugsJacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|May 16, 2017
Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|August 30, 2016
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agentsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|June 15, 2021
Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective changeJacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer|May 20, 2020
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real LifeJacopo Giuliani, Andrea Bonetti
Pageof 14

Showing results (21-30 of 134) with videos related to

Sort By:
Pageof 14
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 7, 2015
A path for diagnosis and therapy of colon cancer: a continuous quality improvementJacopo Giuliani, Marina Marzola
Clinical Lung Cancer|June 2, 2016
The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-InhibitorsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|January 4, 2018
[La combinazione di gemcitabina e oxaliplatino (GEMOX) nel trattamento del carcinoma pancreatico in fase avanzata di malattia: le notizie sulla mia morte sono state esagerate?]Jacopo Giuliani, Andrea Bonetti
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 21, 2013
Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylateJacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease|May 28, 2018
Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costsJacopo Giuliani, Andrea Bonetti
International Journal of Colorectal Disease|September 10, 2018
First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugsJacopo Giuliani, Andrea Bonetti
Clinical Lung Cancer|May 16, 2017
Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic CostsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|August 30, 2016
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agentsJacopo Giuliani, Andrea Bonetti
Recenti Progressi in Medicina|June 15, 2021
Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective changeJacopo Giuliani, Andrea Bonetti
Clinical Colorectal Cancer|May 20, 2020
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real LifeJacopo Giuliani, Andrea Bonetti
Pageof 14